IL1R1 and neoplasm: We found that SC-CM activated CAFs significantly increased PDAC progression in vivo (Fig. 7e–g and Supplementary Fig. S9h–l, G2 vs G1), and IL-1RA treatment substantially suppressed tumor sizes (Fig. 7e–g and Supplementary Fig. S9h–l, G3 vs G2).